Investigation of the short- and long-term effects of donepezil on cognitive function in Alzheimer's disease

Psychogeriatrics

Volumn 9, Issue 1, 2009, Pages 27-33

  Inoue, Jun ^a,c   Hoshino, Ryoichi ^b,c   Nojima, Hidenori ^c   Okamoto, Norio ^c  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Koujin Hospital   (Japan)

^c Okamoto Clinic   (Japan)

Author keywords

Alzheimer type dementia; Behavioral and psychological symptoms of dementia (BPSD); Cognitive function; Donepezil; Long term effect; Short term effect

Indexed keywords

DONEPEZIL; PAROXETINE; TIAPRIDE; ZOLPIDEM; ZOPICLONE;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; COGNITIVE DEFECT; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERACTIVITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SYMPTOMATOLOGY;

EID: 63849137370     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/j.1479-8301.2009.00270.x     Document Type: Article

References (15)

1. Burns A, Rosser M, Hecker J et al. The effects of donepezil in Alzheimer's disease: Results from a multinational trail. Dement Geriatr Cogn Disord 1999; 10: 237-244.
2. Homma A, Takeda M, Imai Y et al. Clinical efficacy and safety of donepezil on coginitive and global function in patients with Alzheimer's disease: 24 week, multicenter, double-blind, placebo-controlled study in Japan. Dement Geriatr Cogn Disord 2000; 11: 299-313.
3. Rogers SL, Doody RS, Prat RD, Ieni JR. Long term efficacy and safety of donepezil in the treatment of Alzheimer's desease: Final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000; 48: 195-203.
4. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer's disease. Arch Neurol 1998; 158: 1021-1031.
5. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24 week, double-blind,placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-145.
6. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8: 67-75.
7. Tohgi H, Homma A, Imai Y et al. Long-term safety and efficacy of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia: 52-week open label study. Rinsho Hyoka 2000; 28: 97-126 (in Japanese).
8. Inoue J, Hoshino R, Nojima H, Okamoto N. Effects of donepezil hydrochloride on cognitive function in patients with Alzheimer-type dementia. Jpn J Geriatr Psychiatry 2007; 18: 993-1002 (in Japanese).
9. Mckhann G, Drachmann D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Service Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
10. Folstein MF, Folstein SE, McHugh PR. 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
11. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566-572.
12. Panek PE, Wanger EE, Kennedy-Zwergel K. A review of projective test finding with older adults. J Pers Assess 1984; 47: 562-582.
13. Hoshino R, Miyasato K, Okamoto N, Kondo N, Ohara K, Arima R. A comparative study of cognitive function in patients with senile dementia of Alzheimer-type and vascular dementia. Jpn J Geriatr Psychiatry 1994; 5: 63-71 (in Japanese).
14. Hoshino R, Miyasato K, Okamoto N, Kondo N, Ohara K, Arima R. A study on the new Rorschach scale for evaluating cognitive function in aged person. Jpn J Geriatr Psychiatry 1996; 7: 409-421 (in Japanese).
15. Courtney C, Farrell D, Gray R et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. Lancet 2004; 26: 2105-2115.